Matches in Nanopublications for { <http://bio2rdf.org/drugbank_resource:DB01393_DB01432> ?p ?o ?g. }
Showing items 1 to 4 of
4
with 100 items per page.
- drugbank_resource:DB01393_DB01432 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB01393_DB01432 label "DDI between Bezafibrate and Cholestyramine - Bile acid sequestrants like cholestyramine may decrease the absorption of fibric acid derivatives like bezafibrate. Therapy modification should be considered. If concomitant therapy is used, separate doses by at least 2 hours to minimize this interaction. Fenofibric acid labeling recommends administration one hour prior to or 4-6 hours after a bile acid sequestrant. [drugbank_resource:DB01393_DB01432]" assertion.
- drugbank_resource:DB01393_DB01432 identifier "drugbank_resource:DB01393_DB01432" assertion.
- drugbank_resource:DB01393_DB01432 title "DDI between Bezafibrate and Cholestyramine - Bile acid sequestrants like cholestyramine may decrease the absorption of fibric acid derivatives like bezafibrate. Therapy modification should be considered. If concomitant therapy is used, separate doses by at least 2 hours to minimize this interaction. Fenofibric acid labeling recommends administration one hour prior to or 4-6 hours after a bile acid sequestrant." assertion.